Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2022 | The exciting new field of HER2-low breast cancer

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the exciting new field of HER2-low breast cancer. The recent Phase III DESTINY-Breast04 (NCT03734029) trial investigated trastuzumab deruxtecan in HER2-low metastatic breast cancer patients (mBC), resulting in a positive progression-free survival (PFS) and overall-survival (OS), indicating future approval of trastuzumab deruxtecan for HER2-low mBC. Although this new subcategory of breast cancer could benefit a large population of patients, Dr Tarantino emphasizes there are still many aspects of HER2-low breast cancer which require elucidation. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.